A Phase I/II study evaluating the safety, tolerability and immunogenicity of Pfizer and BioNTech's mRNA-based combination vaccine candidates for influenza and COVID-19 among healthy adults 18 to 64 years of age show positive topline results. [ read more ]

Moderna’s Combination Flu-COVID-19 Vaccine Demonstrates Immunogenicity

Results from Moderna's Phase I/II clinical trial that evaluated the safety and immunogenicity of its influenza-COVID-19 vaccine, mRNA 1083, showed immunogenicity against all four influenza strains compared to a standard dose of the influenza vaccine, Fluarix, in adults 50 to 64 years of age and against an enhanced influenza vaccine, Fluzone HD, in adults 65 to 79 years of age. In addition, for both age groups, when comparing the mRNA-1083 candidate selected to advance to Phase III, findings showed it achieved hemagglutination inhibition antibody titers similar to or greater than both licensed quadrivalent influenza vaccines and achieved SARS-CoV-2 neutralizing antibody titers similar to the Spikevax bivalent booster in the Phase I/II study. [ read more ]

Intranasal COVID-19 Vaccine Shows High Seroresponse

A Phase I randomized, double-blind, placebo-controlled dose-escalation study in healthy adults, called CDX-CoV-001, has found Codagenix's intranasal COVID-19 vaccine candidate, CoviLiv, showed the vaccine had a high seroresponse rate and induced mucosal immunity in volunteers not previously vaccinated or infected. Furthermore, CoviLiv has been shown to stimulate broad cellular immune responses spanning several SARS-CoV-2 proteins, which are largely conserved across SARS-CoV-2 variants, including those found in Omicron variants. [ read  more ]

This Year's Flu Season Predicted to Be Less Severe

Gavi, an international vaccine alliance, predicts this year's influenza season will be nowhere near as harsh as last year when "reduced exposure to influenza viruses during the COVID-19 pandemic combined with the resurgence of other respiratory infections such as respiratory syncytial virus placed huge pressure on hospital beds in many countries." However, Gavi says its prediction hinges on people getting their seasonal flu vaccine. [ read  more ]

From Amgen

The U.S. Food and Drug Administration has approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for adults patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy; active psoriatic arthritis; moderately to severely active Crohn's disease; and moderately to severely active ulcerative colitis, as well as for pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy; and active psoriatic arthritis. [ read more ]

From Pfizer

The U.S. Food and Drug Administration has approved Pfizer's PENBRAYA, a vaccine for meningococcal groups A, B, C, W and Y. It is the first and only vaccine to protect against the five most common serogroups that cause meningococcal disease in patients aged 10 through 25 years. [ read more ]

From UCB Pharma

UCB Pharma's investigational agent zilucoplan, a complement C5 inhibitor, to treat patients with myasthenia gravis (MG) has been approved by the U.S. Food and Drug Administration under the market name Zilbrysq. The subcutaneously delivered medication is indicated for those with acetylcholine receptor antibody-positive generalized MG. [ read more ]

From Precision Biologic

The U.S. Food and Drug Administration has granted 510(k) clearance to CRYOcheck Factor VIII (FVIII) Deficient Plasma with von Willebrand factor opening the pathway for the company to launch the product in the U.S. The treatment is designed to be used in clinical laboratories to identify human plasma with FVIII deficiency. [ read more ]

• CARBOPLATIN (BPI LABS)

CARBOPLATIN injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents, and for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. It is supplied in 5 mL fill in 10 mL, 15 mL fill in 20 mL, 45 mL fill in 50 mL and 60 mL fill in 100 mL multiple-dose vials.

For more information about CARBOPLATIN, log in to biosupply.fffenterprises.com

• VECURONIUM BROMIDE (FRESENIUS KABI)

VECURONIUM BROMIDE for injection is indicated as an adjunct to general anesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation. It is supplied in 10 mL vials in units of 10.

For more information about VECURONIUM BROMIDE, log in to biosupply.fffenterprises.com

• PLENAMINE (B. BRAUN MEDICAL)

PLENAMINE 15% is indicated as an amino acid (nitrogen) source of parenteral nutrition regimens when the enteral route is inadvisable, inadequate or not possible, as when gastrointestinal absorption is impaired by obstruction, inflammatory disease or its complications, or antineoplastic therapy; bowel rest is needed because of gastrointestinal surgery or its complications such as ileus, fistulae or anastomotic leads; and tube feeding methods alone cannot provide adequate nutrition. It is supplied in sterile and nonpyrogenic flexible plastic bags, pharmacy bulk packages, 1000 mL packaged eight per case and 2000 mL packaged four per case.

For more information about PLENAMINE, log in to biosupply.fffenterprises.com

• CISPLATIN (ACCORD HEALTHCARE)

CISPLATIN injection is a platinum-based drug indicated for the treatment of advanced testicular cancer, advanced ovarian cancer and advanced bladder cancer. It is supplied in 50 mg/50 mL (1 mg/mL) and 100 mg/100 mL (1 mg/mL) multiple-dose amber vials.

For more information about CISPLATIN, log in to biosupply.fffenterprises.com

• YCANTH™ (VERRICA PHARMACEUTICALS)

YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. It is supplied in a sealed glass ampule contained within a single-use applicator and enclosed in a protective paperboard sleeve. Each ampule contains 7 mg/mL of YCANTH.

For more information about YCANTH, log in to biosupply.fffenterprises.com

• NOVAVAX COVID-19 VACCINE (NOVAVAX, INC)

The Novavax COVID-19 Vaccine (Adjuvanted/Protein Subunit) is a vaccine indicated for active immunization to prevent coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older. It is supplied in boxes of 10 doses of two 2.5mL-5 dose multi-dose vials.

For more information about NOVAVAX COVID-19 VACCINE (ADJUVANTED/PROTEIN SUBUNIT), log in to biosupply.fffenterprises.com

• MODERNA COVID-19 VACCINE (mRNA) (MODERNA U.S. INC.)

Moderna COVID-19 Vaccine (mRNA) is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older. It is supplied in cartons of 10 5.5 mL multiple-dose vials and cartons of 10 7.5 mL multiple-dose vials.

For more information about MODERNA COVID-19 VACCINE (mRNA), log in to biosupply.fffenterprises.com

• AREXVY (GLAXOSMITHKLINE BIOLOGICALS)

AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in individuals 60 years of age and older. It is supplied as two components: a single-dose vial of lyophilized antigen component (powder) and a single-dose vial of adjuvant suspension component (liquid) (packaged without syringes or needles) in cartons of 10 vials.

For more information about AREXVY, log in to biosupply.fffenterprises.com

• ASCENIV (ADMA BIOLOGICS)

ASCENIV (immune globulin intravenous, human - slra) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents 12 to 17 years of age. It is supplied in single-use, tamper-evident 50 mL vials containing 5 grams of protein.

For more information about ASCENIV, log in to biosupply.fffenterprises.com

• ABRYSVO (PFIZER INC.)

ABRYSVO is a vaccine indicated for active immunization for the prevention of lower respiration tract disease caused by respiratory syncytial virus in individuals 60 years of age and older. It is supplied in a kit that includes a vial of lyophilized antigen component, a prefilled syringe containing sterile water diluent component and a vial adapter in cartons of one, five and 10 kits.

For more information about ABRYSVO, log in to biosupply.fffenterprises.com

• INDOCIN (ASSERTIO)

INDOCIN is a nonsteroidal anti-inflammatory drug indicated for moderate to severe rheumatoid arthritis, including acute flares of chronic disease; moderate to severe ankylosing spondylitis; moderate to severe osteoarthritis; acute painful shoulder (bursitis and/or tendinitis); and acute gouty arthritis. The 50 mg suppositories (indomethacin suppositories USP) are white, opaque and rectal supplied in boxes of 30.

For more information about INDOCIN, log in to biosupply.fffenterprises.com

• MENVEO ONE-VIAL (GLAXOSMITHKLINE)

MENVEO is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135 in individuals 2 months through 55 years of age. It is supplied in cartons containing five vials of MenCYW-135 liquid conjugate component and cartons containing five vials of MenA lyophilized conjugate component.

For more information about MENVEO ONE-VIAL, log in to biosupply.fffenterprises.com

• CALCIPOTRIENE FOAM (MAYNE PHARMA)

CALCIPOTRIENE FOAM is a vitamin D analog indicated for the topical treatment of plaque psoriasis of the scalp and body in adults and pediatric patients 4 years of age and older. It is supplied in a 60 gram aluminum can.

For more information about CALCIPOTRIENE FOAM, log in to biosupply.fffenterprises.com

• DORYX MPC (MAYNE PHARMA)

DORYX MPC is a tetracycline-class drug indicated for the treatment of rickettsial infections; sexually transmitted infections; respiratory tract infections; specific bacterial infections; ophthalmic infections; anthrax, including inhalational anthrax (post-exposure); alternative treatment for selected infections when penicillin is contraindicated; adjunctive therapy in acute intestinal amebiasis and severe acne; and prophylaxis of malaria. The DORYX MPC (doxycycline hyclate delayed-release) 60 mg and 120 mg tablets are white, oval tablets containing yellow pellets and debossed with "D6" on one face and plain on the other. The 60 mg tablets are supplied in bottles of 60 and 120, and the 120 mg tablet is supplied in bottles of 30.

For more information about DORYX MPC, log in to biosupply.fffenterprises.com

• LIDOCAINE HYDROCHLORIDE 4% (SINTETICA US LLC)

LIDOCAINE HYDROCHLORIDE injection 4% is indicated for the production of topical anesthesia of the mucous membranes of the respiratory tract or the genito-urinary tract. It may be injected trans-tracheally to anesthetize the larynx and trachea, and it may be administered by retrobulbar injection to provide anesthesia for ophthalmic surgery. It is supplied in a pack of 10 200 mg/5 mL single-dose ampules.

For more information about LIDOCAINE HYDROCHLORIDE 4%, log in to biosupply.fffenterprises.com

• LIDOCAINE HYDROCHLORIDE 1%/2% (SINTETICA US LLC)

LIDOCAINE HYDROCHLORIDE injection 1% and 2% are indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection, by peripheral nerve block techniques such as brachial plexus and intercostal, and by central neural techniques such as lumbar and caudal epidural blocks when the accepted procedures for these techniques as described in standard textbooks are observed. The 1% injection is supplied in a pack of 10 20 mg/2mL, 50 mg/5 mL and 100 mg/10 mL single-dose ampules. The 2% injection is supplied in 40 mg/2 mL, 100 mg/5 mL and 200 mg/10 mL single-dose ampules.

For more information about LIDOCAINE HYDROCHLORIDE 1%/2%, log in to biosupply.fffenterprises.com

• HEPARIN SODIUM (TECHDOW)

HEPARIN SODIUM injection is an anticoagulant indicated for prophylaxis and treatment of venous thrombosis and pulmonary embolism; prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease; atrial fibrillation with embolization; treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); prevention of clotting in arterial and cardiac surgery; prophylaxis and treatment of peripheral arterial embolism; and use as an anticoagulant in blood transfusions, extracorporeal circulation and dialysis procedures. It is supplied in a concentration of 1,000 mL in 2 mL single-dose vials and 1 mL, 10 mL and 30 mL multiple-dose vials; in a concentration of 5,000 mL in 1 mL and 10 mL multiple-dose vials; in a concentration of 10,000 mL in 1 mL and 5 mL multiple-dose vials; and in a concentration of 20,000 mL in 1 mL multiple-dose vials.

For more information about HEPARIN SODIUM, log in to biosupply.fffenterprises.com

• MENQUADFI (SANOFI)

MENQUADFI meningococcal (groups A, C, Y, W) conjugate vaccine solution for intramuscular injection is indicated for active immunization for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and Y for use in individuals 2 years of age and older. It is supplied in a single-dose vial in packages of five vials.

For more information about MENQUADFI, log in to biosupply.fffenterprises.com

• SODIUM BICARBONATE (EXELA PHARMA SCIENCES)

SODIUM BICARBONATE injection, USP, is indicated 1) in the treatment of metabolic acidosis that may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis, 2) in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products and 3) in severe diarrhea that is often accompanied by a significant loss of bicarbonate. It is supplied in 50 mL vials with either 20 or 25 vials per carton, and 10 mL vials with 25 vials per carton.

For more information about SODIUM BICARBONATE, log in to biosupply.fffenterprises.com

• PRIORIX (GLAXOSMITHKLINE)

PRIORIX (vaccine, live) is indicated for active immunization for the prevention of measles, mumps and rubella in individuals 12 months of age and older. It is supplied in a box containing 10 single-dose vials of lyophilized antigen component and 10 single-dose prefilled ungraduated syringes of sterile water diluent (packaged without needles). After reconstitution, each vial contains one dose (approximately 0.5 mL) of PRIORIX.

For more information about PRIORIX, log in to biosupply.fffenterprises.com

These products can be ordered from FFF Enterprises' BioSupply Online Ordering System or by calling
Wow! Customer Care at (800) 843-7477.

Current Medicare IVIG / SCIG Rates

Rates per gram are effective October 1, 2023, through December. 31, 2023.

Resources

FFF customers may order the following complementary resources to help you with your practice: